Torrent Pharmaceuticals announced its financial results for the second quarter of FY27, reporting a significant 51% year-over-year increase in revenue to ₹4,979 crore. The company also saw a substantial 54% rise in its operating EBITDA to ₹1,666 crore. This robust performance was driven by strong base India business revenues and post-merger integration impacting JB business.
Torrent Pharma Reports Strong Q2 FY27 Results
Torrent Pharmaceuticals Limited (the “Company”) has announced its financial results for the second quarter and half-year ended September 30, 2026 (Q2 FY27). The company posted a substantial 51% year-over-year increase in revenue, reaching ₹4,979 crore for the quarter. This growth was underpinned by a robust performance in its base India business, which saw revenues climb by 20%.
Key Financial Highlights
Q2 FY27 Performance:
- Revenues: Increased by 51% YoY to ₹4,979 crore.
- Gross Profit: Grew by 50.1% YoY to ₹3,755 crore, with a Gross Margin of 75.4%.
- Operating EBITDA: Rose by 54% YoY to ₹1,666 crore, with an improved margin of 33.5%.
- Net Profit After Tax (PAT): Reported at ₹534 crore, although this represented a 9.6% decrease YoY.
- R&D Spend: Increased by 35.0% YoY to ₹211 crore, representing 4.2% of revenues.
Half-Yearly Performance (H1 FY27):
- Revenues reached ₹9,900 crore, up 52.8% YoY.
- Operating EBITDA stood at ₹3,330 crore, a 57.4% YoY increase.
- PAT was ₹1,100 crore, a decrease of 3.4% YoY.
Strategic and Operational Insights
The company highlighted that the post-merger integration with JB Pharma has led to a transient impact on JB business revenues. The India business continues to show strong momentum, with revenues growing 20% against an IPM growth of 12%. Torrent’s Gx Semaglutide achieved a market share of 32% in Q2 FY27. Key international markets also showed mixed results, with Brazil revenues up 38% and US revenues up 24%, while Germany experienced a 7% revenue decline due to supply disruptions.
The financial results were approved by the Board of Directors on October 23, 2026. The standalone financial results are also enclosed as Annexure A, and the limited review report on unaudited consolidated financial results is provided.
Source: BSE
